RE:RE:cash into 2025?lscfa wrote: I wish these damn drug development co.s were forced to do PEAs like the resource industry to disclose the expected capex needed for phases 1,2,3 trials and marketing costs when commercialized.
H.C. Wainwright has a US$15 price target for AEZS likely supported by a discounted cashflow analysis. The merged company should support more analysts. A NASDAQ listing and a US$100 million market cap should attract a whole new level of interest. Research Capital and Bloom Burton were used for the merger. With pediatric approval for the diagnostic, and 100L PGX scale-up and commercial licensing deals on the diagnostic test and PGX there will be validation. The avenanthramide pill safety/tolerability and efficacy data in patients with inflamation will provide something to analyze. The fibrosis drug could both be in human testing soon. The wound healing program could also be partnered and in human trials. AEZS Aim Biologicals could also move to clinical trials. CZO could advance the immune booster and has done a net present value analysis previously. Things will have matured to clinical trials, and to key validation important for analysts. Gilles is getting a NASDAQ listing to support a higher profile in the capital markets.
CZO is leaving the pre-commercial R&D